Dendritic cell immunotherapy: clinical outcomes

Vasso Apostolopoulos, Geoffrey A. Pietersz, Anastasios Tsibanis, Annivas Tsikkinis, Lily Stojanovska, Ian F.C. McKenzie, Stamatis Vassilaros

Research output: Contribution to journalReview articlepeer-review

37 Citations (Scopus)


The use of tumour-associated antigens for cancer immunotherapy studies is exacerbated by tolerance to these self-antigens. Tolerance may be broken by using ex vivo monocyte-derived dendritic cells (DCs) pulsed with self-antigens. Targeting tumour-associated antigens directly to DCs in vivo is an alternative and simpler strategy. The identification of cell surface receptors on DCs, and targeting antigens to DC receptors, has become a popular approach for inducing effective immune responses against cancer antigens. Many years ago, we demonstrated that targeting the mannose receptor on macrophages using the carbohydrate mannan to DCs led to appropriate immune responses and tumour protection in animal models. We conducted Phase I, I/II and II, clinical trials demonstrating the effectiveness of oxidised mannan-MUC1 in patients with adenocarcinomas. Here we summarise DC targeting approaches and their efficacy in human clinical trials.

Original languageEnglish
Article numbere21
JournalClinical and Translational Immunology
Issue number7
Publication statusPublished - Jul 1 2014
Externally publishedYes

ASJC Scopus subject areas

  • General Nursing
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Dendritic cell immunotherapy: clinical outcomes'. Together they form a unique fingerprint.

Cite this